Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × Interleukin-2 × 90 days × Clear all

NCT05681780 2026-03-31

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms